Today, NBE-Therapeutics announces that Prof. Alfred Zippelius, who is Full Professor for Translational Oncology and Cancer Immunology at the Departments of Medical Oncology and Biomedicine of University Hospital Basel, joined the Scientific Advisory Board of NBE-Therapeutics. With his experience in performing cutting edge clinical research and translating his research into clinical applications, Prof. Zippelius will be of critical importance for providing guidance with relevant preclinical models and their translation into clinical protocols for NBE-Therapeutics lead ADC development programs. In his function as Professor for Translational Oncology, he not only has vast experience in the area of clinical laboratory research involving antibody drug conjugates (ADCs) and other antibody-based therapies, but he is also responsible for conducting and supervising clinical trials with cancer patients at the University Hospital Basel, Switzerland. NBE-Therapeutics CEO, Ulf Grawunder, comments: "With the appointment of Alfred Zippelius, who is a renowned clinical expert in the field of Immuno-Oncology and Translational Oncology, NBE-Therapeutics will benefit tremendously in its efforts to develop its lead Antibody Drug Conjugate compounds as quickly as possible from the lab to the clinic, such that newest treatment options become available for cancer patients in need. The appointment of Prof. Zippelius perfectly complements the expertise of NBE-Therapeutics Scientific Advisory Board in antibody & ADC development." Most recently, Prof. Zippelius and NBE-Therapeutics have also been awarded a CHF 600K SystemsX research grant together with Prof. Sai Reddy from ETH, Zürich, dedicated to study the influence of targeted ADC Therapies on the immune response against the tumor.